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Introduction 
Diabetes has been estimated to affect 285 million people 
worldwide and 24 million in the U.S. [1, 2]. The high blood 
glucose concentrations that are characteristic of this meta-
bolic disease are caused by a deficiency in insulin produc-
tion or an impaired efficiency in insulin action [1-3]. These 
elevated concentrations of glucose are often combined with 
other factors, such as high blood pressure and altered lipid 
levels, which can lead to cardiovascular disease, kidney or 
liver damage, and blindness [1-4]. Many of these compli-
cations are associated with the non-enzymatic glycation of 
proteins [5]. 
Glycation is a process that is enhanced during diabe-
tes. This process begins with the reaction of a free amine 
group on a protein with an aldehyde group on a reducing 
sugar, such as glucose, to form a reversible Schiff base. A 
slow rearrangement of this Schiff base can produce a more 
stable fructosamine residue, or Amadori product [6-8]. Nu-
merous studies have indicated that glycation can produce 
structural and functional modifications in proteins with 
relatively long half-lives, such as collagen, lens crystalline, 
and hemoglobin [4, 5, 8-10]. Glycation can also occur with 
human serum albumin (HSA), the main protein in serum 
[6, 7, 9-14]. For modern affinity-based detection methods, 
the reported reference range for glycated HSA in normal 
individuals is typically 0.6-3%, with this amount increasing 
by two- to five-fold during type 2 diabetes [14, 15]. 
The glycation of HSA has been of recent interest due to 
the importance of this protein as a carrier agent for many 
drugs and endogenous compounds in the circulatory sys-
tem [10-14]. Sulfonylurea drugs are a set of pharmaceuti-
cal agents that are known to have significant binding to 
HSA [11, 14, 16-25]. These drugs are used to treat type 2 
diabetes by stimulating the secretion of insulin [16]. Some 
common sulfonylurea drugs are acetohexamide, tolbu-
tamide and gliclazide (see structures in Figure 1). These 
drugs are all highly bound in blood to HSA and have 
been shown to have significant interactions at a set of high 
affinity sites that include both of the major drug interac-
tion sites of this protein: Sudlow sites I and II, as shown 
in Figure 2 [16-23]. In addition, recent studies have found 
that glycation can alter the binding of sulfonylurea drugs 
with HSA [20-25]. The association equilibrium constants 
for the high affinity interactions of these drugs with nor-
mal HSA, and with HSA that has glycation levels similar 
to those seen in diabetes, have been reported to be in the 
range of 1.3-4.2 × 105 M–1 for acetohexamide, 0.87-1.2 × 105 
M–1 for tolbutamide, and 0.7-1.0 × 105 M–1 for gliclazide at 
pH 7.4 and 37°C [19, 21-23].  
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Abstract
The presence of elevated glucose concentrations in diabetes is a metabolic change that leads to an increase in the 
amount of non-enzymatic glycation that occurs for serum proteins. One protein that is affected by this process is 
the main serum protein, human serum albumin (HSA), which is also an important carrier agent for many drugs 
and fatty acids in the circulatory system. Sulfonylurea drugs, used to treat type 2 diabetes, are known to have sig-
nificant binding to HSA. This study employed ultrafiltration and high-performance affinity chromatography to ex-
amine the effects of HSA glycation on the interactions of several sulfonylurea drugs (i.e., acetohexamide, tolbuta-
mide and gliclazide) with fatty acids, whose concentrations in serum are also affected by diabetes. Similar overall 
changes in binding were noted for these drugs with normal HSA or glycated HSA and in the presence of the fatty 
acids. For most of the tested drugs, the addition of physiological levels of the fatty acids to normal HSA and gly-
cated HSA produced weaker binding. At low fatty acid concentrations, many of these systems followed a direct 
competition model while others involved a mixed-mode interaction. In some cases, there was a change in the in-
teraction mechanism between normal HSA and glycated HSA, as seen with linoleic acid. Systems with only direct 
competition also gave notable changes in the affinities of fatty acids at their sites of drug competition when com-
paring normal HSA and glycated HSA. This research demonstrated the importance of considering how changes 
in the concentrations and types of metabolites (e.g., in this case, glucose and fatty acids) can alter the function of a 
protein such as HSA and its ability to interact with drugs or other agents. 
Keywords: Diabetes, drug-protein binding, fatty acids, glycation, high-performance affinity chromatography, hu-
man serum albumin, sulfonylurea drugs, ultrafiltration  
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Another metabolic change that occurs during diabetes is 
the presence of elevated concentrations of free fatty acids 
in serum [26-28]. Several studies have noted that increased 
levels of free fatty acids can contribute to the pathogene-
sis of hypertension, cardiovascular risk factors, and con-
ditions such as atherosclerosis [29]. In addition, high glu-
cose levels and elevated fatty acid concentrations in serum 
have been correlated with impaired sensitivity, increased 
inflammation, and oxidative stress, among other meta-
bolic complications [30, 31]. HSA binds to many fatty ac-
ids, some of which are shown in Figure 1 [32]. In addition, 
it is known that some fatty acids can have direct competi-
tion with drugs or lead to allosteric effects during the bind-
ing of drugs and other solutes with HSA [14, 33-35]. There 
are a number of binding regions for fatty acids on HSA, 
as illustrated in Figure 2 [33, 35-39], with the strongest of 
these interactions having association equilibrium constants 
in the range of 105 to 108 M–1 [33, 39]. 
Figure 1. Structures of the sulfonylurea drugs and fatty acids that were examined in this study. 
Figure 2. Structure of HSA, including the 
regions that bind palmitic acid and the major 
drug binding sites of this protein (i.e., Sudlow 
sites I and II). This structure was generated 
using Protein Data Bank (PDB) file ID: 1E7H 
[33].   
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A recent report used a chromatographic high-through-
put screening method to compare the overall effects of 
glycation and the presence of fatty acids on the bind-
ing of several sulfonylurea drugs with HSA [20]. It was 
found that there was a significant increase in retention 
(i.e., stronger binding) for drugs such as acetohexamide, 
tolbutamide and gliclazide in going from normal HSA to 
glycated HSA. It was also noted that the addition of low 
levels of fatty acids led to lower binding for these drugs 
with both normal HSA and glycated HSA. This current 
study examined these effects further by using both ultra-
filtration and high-performance affinity chromatography 
(HPAC) [14, 40, 41]. Ultrafiltration was utilized to deter-
mine the overall effects of various fatty acids at physio-
logical concentrations on the binding of acetohexamide, 
tolbutamide and gliclazide with normal HSA and gly-
cated HSA. Experiments based on HPAC and competition 
experiments were used to examine these interactions in 
more detail, particularly in the presence of low concentra-
tions of fatty acids. The results of this study were then uti-
lized to provide further clues as to how the interactions of 
sulfonylurea drugs and fatty acids with HSA may change 
during metabolic diseases such as diabetes. 
Materials and Methods 
Reagents 
The HSA (essentially fatty acid free) and glycated HSA 
used in the chromatographic studies (3.6 mol hexose/mol 
HSA, essentially fatty acid free) [20] were from Sigma- Al-
drich (St. Louis, MO, USA). The sulfonylurea drugs and 
fatty acids that were examined in this study (see summary 
in Figure 1) were also obtained from Sigma-Aldrich. The 
glycated HSA used in the ultrafiltration studies was pre-
pared from normal HSA according to a previous method 
[20, 21] and contained 3.4 mol hexose/mol HSA, as deter-
mined by using a fructosamine assay from Diazyme Lab-
oratories (Poway, CA, USA). The modification levels that 
were present in the glycated HSA samples were repre-
sentative of what might be present during uncontrolled 
or advanced diabetes [20-23]. Sterilized culture tubes (17 
× 100 mm) and siliconized polypropylene microcentri-
fuge tubes (13 × 40 mm) were obtained from Fisher Sci-
entific (Pittsburgh, PA, USA). Slide- A-Lyzer dialysis cas-
settes (7 kDa MW cutoff; 12–30 mL sample volume) were 
purchased from Thermo Scientific (Rockford, IL, USA). 
Econo-Pac 10 DG disposable desalting columns were ac-
quired from Bio-Rad Laboratories (Hercules, CA, USA). 
Nucleosil Si-300 silica (7 μm particle diameter, 300 Å pore 
size) was obtained from Macherey-Nagel (Düren, Ger-
many). Other chemicals were reagent grade or better. All 
buffers and aqueous solutions were prepared using water 
from a Nanopure water system (Barnstead, Dubuque, IA) 
and were filtered using 0.2 μm GNWP nylon filters from 
Millipore (Billerica, MA, USA). 
Apparatus 
Ultrafiltration was performed using Centrifree Mic-
ropartition devices (30 kDa MW cutoff, 0.15–1.0 mL sam-
ple capacity) from Amicon (Danvers, MA, USA) and a 
5702RH temperature-controlled centrifuge from Eppendorf 
(New York, NY, USA) equipped with a fixed-angle centri-
fuge rotor from VWR (West Chester, PA, USA). Flow-injec-
tion analysis of the drug content in each filtrate was carried 
out by using a Jasco 2000 HPLC system (Easton, MD, USA) 
that contained a DG-2080-53 degasser, a PU- 2080 pump, 
an AS-2057 autosampler equipped with a 100 μL sample 
loop (operated in the partial loop injection mode), and a 
UV-2075 absorbance detector. These system components 
were controlled by a Jasco LC-Net II/ADC system and us-
ing EZ Chrom SI software (Scientific Software, Pleasanton, 
CA, USA). The peaks detected in the injected samples were 
integrated using PeakFit 4.12 (Sea-Solve Software, San Jose, 
CA, USA). Non-linear regression of the data was carried 
out by utilizing Data Fit 8.1.69 (Oakdale, PA, USA). 
The system employed in the chromatographic measure-
ments consisted of a Hitachi L-6000 pump (Pleasanton, CA, 
USA), a ThermoSeparations SpectraSystem AS3000 autos-
ampler (Waltham, MA, USA) with a 10 μL sample loop, 
and a Waters 481 UV detector (Milford, MA, USA). Detec-
tion was performed at 248 nm for acetohexamide and at 
226 nm for gliclazide and tolbutamide. The columns were 
kept at 37 (± 0.1) °C by using a water jacket from Fisher 
Scientific and a 2067 CH/P recirculating water bath from 
Forma Scientific (Marietta, OH, USA). Data were acquired 
using Lab-View 8.0 (National Instruments, Austin, TX, 
USA) and processed using PeakFit 4.12. 
Ultrafiltration Studies 
All solutions of drugs, fatty acids and proteins used in 
the ultrafiltration studies were prepared in pH 7.4, 0.067 M 
potassium phosphate buffer. To study the effect of fatty ac-
ids on the binding of sulfonylurea drugs to HSA and gly-
cated HSA, fatty acid solutions were prepared over the 
following ranges of concentrations, which included the 
typical physiological levels of these solutes and concentra-
tions that can be found in serum during diabetes [42-44]: 
lauric acid (0-16 μM), linoleic acid (0-300 μM), myristic acid 
(0-220 μM), oleic acid (0-600 μM), palmitic acid (0-400 μM), 
and stearic acid (0-80 μM). The samples for these fatty acid 
studies were prepared by mixing 0.25 mL of a fatty acid so-
lution with 0.5 mL of an HSA or glycated HSA solution, 
giving a final protein concentration of 260–290 μM. The 
fatty acid/protein mixture was incubated at 37ºC in a wa-
ter bath for 24 h, followed by the addition of 0.5 mL of a 
given drug at a final fixed concentration of 200 μM (Note: 
this concentration represents a common therapeutic level 
for acetohexamide and tolbutamide [45] and allowed for 
easy detection of the free drug fractions). Although sulfo-
nylureas are weak acids with pKa values in the range of 5.2 
to 6.2, all of the tested drug solutions had a pH that dif-
fered by less than 0.05 units from pH 7.4; these pH values 
were found to be quite stable and to change by less than 
0.05 units over the entire course of the binding studies [21-
23]. The drug/fatty acid/protein mixture was incubated 
at 37ºC for 45 min in a water bath; the use of longer incu-
bation times up to 90 min did not produce any significant 
change in the final results. 
Prior to ultrafiltration, the membrane in each ultrafil-
tration device was rinsed three times with deionized wa-
ter and pH 7.4, 0.067 M potassium phosphate buffer to re-
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duce interferences by any contaminants or preservatives 
that may have been present. The ultrafiltration device was 
spun for at least 15 min at 1,500 ×g after rinsing to avoid di-
lution errors due to the presence of any remaining rinse so-
lution in the device; the volume of rinse solution that re-
mained after this step was less than ~10 μL. 
The ultrafiltration experiments were carried out by 
placing a 1 mL aliquot of each test mixture into a Centri-
free micropartition device and spinning this mixture at 
1,500 ×g for 25 min at 37 ºC. The filtrate was collected and 
analyzed for its drug content by injecting 5 μL aliquots in 
triplicate onto a flow-injection analysis system with no 
column present. These injections were made at 0.5 mL/
min and in the presence of pH 7.4, 0.067 M potassium 
phosphate buffer. The eluting drug fractions were moni-
tored at 257 nm for acetohexamide and at 227 nm for tol-
butamide or gliclazide. A background correction for any 
contaminants or preservatives remaining in the filtrate 
from the ultrafiltration device was made by carrying out 
similar measurements on filtrates for 0.5 mL samples that 
contained only HSA or glycated HSA in pH 7.4, 0.067 M 
potassium phosphate buffer. 
Chromatographic Studies 
The normal HSA and glycated HSA columns were pre-
pared by converting Nucleosil Si-300 silica into a diol-
bonded form and then using the Schiff base coupling 
method, as described previously [19-21]. As noted in pre-
vious work, the immobilization of HSA by this approach 
mainly occurs through the N-terminus or lysines that 
are not located at Sudlow sites I and II [43] and has been 
shown to provide columns containing immobilized normal 
HSA or glycated HSA that are good models for the soluble 
forms of these proteins [19-24]. These supports were found 
by a bicinchoninic acid (BCA) protein assay to contain 25 (± 
2) mg HSA or 15.4 (± 0.7) mg glycated HSA per g silica, as 
determined in triplicate by using HSA as the standard and 
diol-bonded silica as the blank. The supports were packed 
into separate 2.0 cm × 2.1 mm I.D. columns at 3500 psi (24.1 
MPa). A pH 7.4, 0.067 M potassium phosphate buffer was 
used as the packing solution, and the columns were stored 
in this buffer at 4°C when not in use. Control columns were 
prepared in the same manner but with no protein being 
added during the immobilization step. All columns were 
used over the course of a few months and were found to 
provide stable retention factors under these operating con-
ditions [19-24]. 
The mobile phase used in the chromatographic-based 
competition studies contained pH 7.4, 0.067 M phosphate 
buffer or the same buffer plus a known concentration of the 
fatty acid to be tested. The fatty acid concentrations that 
were used were generally 100-fold lower than physiolog-
ical levels or those seen in diabetes, which made it possi-
ble to monitor changes in the high affinity binding of the 
fatty acids during the chromatographic studies [20, 42-
44]. The samples contained 5 μM of the desired drug in 
the mobile phase, which was used as a tracer to probe any 
changes in retention for the drug at its binding sites on 
HSA [19, 22-24]. Under the conditions used in these stud-
ies, approximately 82-99% of the observed drug retention 
in the absence of any fatty acids should have been due to 
interactions at Sudlow sites I and II [25]. These drug sam-
ples were injected in triplicate at 37oC and 0.5 mL/min. 
No significant changes in retention occurred when using 
slightly higher sample concentrations of the drugs, indicat-
ing that linear elution conditions were present, or when us-
ing slower flow rates for the chromatographic studies. In-
jections of 5 μM sodium nitrate (i.e., a non-retained solute 
for HSA columns [19-24], which was detected at 205 nm) 
were made to measure the void time of each column. Stud-
ies with the control column indicated that the tested drugs 
had no significant non-specific retention to the support 
(i.e., less than 3% of the total retention noted on the normal 
HSA or glycated HSA columns). 
Results and Discussion 
Effects of Fatty Acids on the Overall Binding of Sulfonyl-
urea Drugs to Normal or Glycated HSA 
Ultrafiltration studies were used to first examine the 
overall effects of glycation versus fatty acids on the bind-
ing of sulfonylureas to HSA. This method was utilized to 
compare the changes in the free, or non-protein bound, 
fraction of each drug, which was used as an index of the 
total binding of these drugs with normal HSA or glycated 
HSA. Some typical experimental results are provided in 
Figure 3, which show how the measured free drug frac-
tions changed for normal HSA as increasing concentra-
tions of linoleic acid were added. Tables 1 and 2 summa-
rize the changes in the free drug concentrations that were 
obtained in these studies with normal HSA or glycated 
HSA and in the absence or presence of various fatty ac-
ids that are commonly found in blood. In each case, both 
normal concentrations (Table 1) and elevated concentra-
tions (Table 2) of these fatty acids, as found during diabe-
tes, were tested. 
For most of the combinations of fatty acids, drugs and 
types of HSA that were examined, the change in free drug 
concentration that was measured as the fatty acid concen-
tration was increased gave a reasonably good fit to a linear 
model. Some examples of such fits are shown in Figure 3 
for normal HSA and linoleic acid. In this figure, the correla-
tion coefficients of the best-fit responses for acetohexamide, 
gliclazide and tolbutamide were 0.784 (n = 8), 0.918 (n = 9), 
and 0.931 (n = 9). Similar results were seen for most of the 
other combinations of fatty acids, drugs and types of HSA 
that were examined. The corresponding best-fit lines typ-
ically had a positive slope, with the only exception occur-
ring for gliclazide in the presence of oleic acid and normal 
HSA, as discussed in the next paragraph. There were also 
a few situations in which a large initial change in free drug 
concentration at low fatty acid conditions required the use 
of a non-linear fit or a multi-linear fit to describe the data. 
This type of behavior was observed when using normal 
HSA and tolbutamide in the presence of oleic acid or stea-
ric acid and acetohexamide in the presence of palmitic acid, 
as well as for gliclazide and glycated HSA in the presence 
of oleic acid. However, in each of these cases a net positive 
slope was still obtained.  
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Figure 3. Effect of increasing the concentration of linoleic acid on the free drug concentration of acetohexamide (■), gliclazide (♦) 
and tolbutamide (▲) in the presence of fixed total concentrations of each drug and normal HSA. Each point represents the aver-
age of three measurements and the error bars represent a range of ± 1 S.D.   
Table 1. Effects of Normal Concentrations of Fatty Acids on the Binding of Sulfonylurea Drugs to HSA and Glycated HSA 
                             Change in Free Drug Concentrationa 
 Fatty Acid  Acetohexamide  Gliclazide  Tolbutamide 
Lauric acid (0.1-6 μM) 
 Normal HSA  0.2-10%  0.03-2.1%b  0.04-2.7% 
 Glycated HSA  0.04-2.6%b,c  0.1-7%  0.02-1.0%b,c 
Linoleic acid (20-93 μM) 
 Normal HSA  3.2-15%  5-24%  2.4-11% 
 Glycated HSA  6-29%c  5-23%c  8-38% 
Myristic acid (3-24 μM) 
 Normal HSA  2.6-20%  0.6-4.6%b  0.04-0.3%b 
 Glycated HSA  1.0-8%c  0.3-2.5%c  0.5-4.2%c 
Oleic acid (33-182 μM) 
 Normal HSA  17-93%  -1.5-8%a  9-35%d 
 Glycated HSA  0.4-2.1%  9-21%b  1.5-8% 
Palmitic acid (25-171 μM) 
 Normal HSA  4.0-27%d  4.3-29%  4.3-29% 
 Glycated HSA  1.5-10%c  1.3-9%  5-36%c 
Stearic acid (6-57 μM) 
 Normal HSA  0.6-5%  4.4-41%  19-31%d 
 Glycated HSA  0.6-5%c  1.5-14%  2.8-25%c 
a. All of the indicated changes are relative to the free concentration measured for a drug in the absence of any fatty acid at pH 7.4 
and 37°C; the given values represent an increase in the free drug concentration, except for the case of gliclazide in the presence 
of oleic acid and normal HSA. 
b. All changes in the free drug concentration, except those indicated by this footnote, were significantly different at the 95% 
confidence level when comparing the results measured at the upper end of the normal fatty acid concentration range versus the 
results obtained when no fatty acid was present. 
c. All changes in the free drug concentration, except those indicated by this footnote, were significantly different at the 95% 
confidence level when comparing the results measured at the upper end of the normal fatty acid concentration range for normal 
HSA versus glycated HSA. 
d. Non-linear regression or a combination of linear regions were used in this case because some curvature was noted in the 
corresponding plot of free drug concentration versus fatty acid concentration. 
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The results in Table 1 and 2 show that almost all of the 
tested combinations of drugs and fatty acids resulted in 
an increase in free drug concentration, or weaker drug 
binding, as the concentration of fatty acids was increased. 
This general observation agrees with the previous screen-
ing studies that used trace amounts of the same drugs 
along with immobilized preparations of normal HSA or 
glycated HSA and nanomolar concentrations of the given 
fatty acids [20]. This decrease in drug binding could be 
produced by direct competition of a fatty acid with a drug 
for binding sites or through negative allosteric interac-
tions [34, 35]. The presence for either type of interaction 
fits with the fact that some fatty acids may bind either at 
or near Sudlow sites I and II, as illustrated for palmitic 
acid in Figure 2. The only case in which different behavior 
was noted occurred for gliclazide in the presence of oleic 
acid and normal HSA, for which a decrease in free drug 
concentration and stronger drug binding was seen as the 
amount of added fatty acid was increased. This behavior 
can occur if a positive allosteric effect is present during 
the binding of a fatty acid and a drug with HSA [35]. 
It was noted that the same general changes in free drug 
concentrations in the presence of fatty acids tended to 
occur for each drug with normal HSA or glycated HSA. 
This observation was again in agreement with the previ-
ous screening studies using immobilized forms of these 
proteins [20]. Some differences did occur in the relative 
size of the effects for normal versus glycated HSA (e.g., 
as seen in some of the results for linoleic acid and palmitic 
acid); however, the most significant difference occurred in 
the results for gliclazide and acetohexamide in the pres-
ence of oleic acid. For gliclazide that was combined with 
normal HSA, a decrease in free drug concentration was 
seen as the amount of oleic acid was increased, but for the 
glycated HSA an increase in free drug concentration was 
noted under otherwise identical conditions. For acetohex-
amide, a large increase in free drug concentration was 
measured in the presence of oleic acid and normal HSA, 
while only a small increase was seen for the same drug in 
the presence of oleic acid and glycated HSA. 
Myristic acid (i.e., a medium length saturated fatty 
acid) gave only a small or moderate change in binding for 
Table 2. Effects of Elevated Concentrations of Fatty Acids on the Binding of Sulfonylurea Drugs to HSA and Glycated HSA 
                      Change in Free  Drug Concentrationa 
 Fatty Acid Acetohexamide  Gliclazide  Tolbutamide 
Lauric acid (up to 9 μM) 
 Normal HSA  13%  3.1%  3.9% 
 Glycated HSA  3.8%b  10%  1.5%b,c 
Linoleic acid (up to 300 μM) 
 Normal HSA  49%  76%  36% 
 Glycated HSA  94%  76%c  120% 
Myristic acid (up to 43 μM) 
 Normal HSA  37%  8%  0.6%b 
 Glycated HSA  15%  4.5%c  8%c 
Oleic acid (up to 600 μM) 
 Normal HSA  310%  -27%a  53% 
 Glycated HSA  7%  36%  27% 
Palmitic acid (up to 400 μM) 
 Normal HSA  64%  68%  69% 
 Glycated HSA  23%  21%  85% 
Stearic acid (up to 80 μM) 
 Normal HSA  8%  57%  37% 
 Glycated HSA  7%c  20%  36%c 
a. All of the indicated changes are relative to the free concentration measured for a drug in the absence of any fatty acid at pH 7.4 
and 37°C. Each of the given values represents an increase in the free drug concentration, except for the case of gliclazide in the 
presence of oleic acid and normal HSA. 
b. All changes in the free drug concentration, except those indicated by this footnote, were significantly different at the 95% 
confidence level when comparing the results measured at the upper end of the elevated fatty acid concentration range versus the 
results obtained when no fatty acid was present. 
c. All changes in the free drug concentration, except those indicated by this footnote, were significantly different at the 95% 
confidence level when comparing the results measured at the upper end of the normal fatty acid concentration range for normal 
HSA versus glycated HSA.
F A t t y  A c i d s ,  g l y c A t i o n ,  A n d  d r u g  i n t e r A c t i o n s  w i t H  H u m A n  s e r u m  A l B u m i n   245
each of the tested drugs even at elevated fatty acid levels 
(i.e., less than 8% change for gliclazide and tolbutamide at 
43 μM myristic acid, and a change of 37% or less for ace-
tohexamide). Small or moderate changes in binding were 
also noted for each drug in the presence of medium-to- 
long chain saturated fatty acids such as lauric acid (<13% 
change) and stearic acid (<57% change). Larger changes in 
binding were observed for these drugs in the presence of 
linoleic acid (i.e., a long chain unsaturated fatty acid) and 
palmitic acid (a long chain saturated fatty acid). Both of 
these fatty acids have relatively high concentrations in se-
rum and gave moderate-to-large changes in binding for 
the sulfonylurea drugs (i.e., a 36-120% change and a 21-
85% change, respectively, at elevated fatty acid levels). All 
of these general trends agree with those noted for immo-
bilized normal HSA and glycated HSA at lower fatty acid 
concentrations [20]. Oleic acid is an unsaturated long chain 
fatty acid that also occurs at a relatively high concentration 
in serum. The small-to-moderate changes in binding seen 
in the presence of oleic acid for tolbutamide with normal 
HSA and for all of the drugs in the presence of this fatty 
acid and glycated HSA further agreed with the results in 
Reference [20]. 
Effects of Low Levels of Fatty Acids on the Binding of Sul-
fonylurea Drugs with HSA 
The next stage of this study used competition studies 
and HPAC to more closely examine the changes in bind-
ing that occurred for sulfonylurea drugs in the presence of 
fatty acids and normal HSA or glycated HSA. The analy-
sis of these systems was simplified by using fatty acid con-
centrations that were up to 100-fold below the levels found 
in serum, as employed previously in a screening study to 
emphasize the initial, high affinity interactions for these 
fatty acids with HSA [20]. In this current report these con-
ditions were used to examine the competition of these fatty 
acids with sulfonylurea drugs in a quantitative fashion and 
to compare the types of interactions that were occurring on 
normal HSA and glycated HSA between these fatty acids 
and drugs. During these experiments, the retention time 
(tR) for a small amount of an injected drug was measured 
and used to calculate the retention factor for the same drug 
(k) by using the relationship k = (tR – tM)/tM, where tM is 
the elution time for a nonretained solution (e.g., sodium ni-
trate for the columns used in this study). Examples of some 
typical chromatograms that are obtained through this ap-
proach for both normal HSA and glycated HSA columns 
can be found in Reference [20]. 
In this study, the change in the retention factor for a 
drug that was injected onto a normal HSA column or gly-
cated HSA column was examined as various concentrations 
of fatty acids were added to the mobile phase. As described 
previously for other systems, the presence of no significant 
changes in the value of k for a drug as the fatty acid concen-
tration is increased would indicate that no competition or al-
losteric effects are occurring between the drug and fatty acid 
on the column [40]. A decrease in k with an increase in the 
concentration of a fatty acid may be caused by direct com-
petition of these agents or through negative allosteric effects, 
while an increase in k could be produced through positive 
allosteric effects. A review of the equations and models that 
can be used to differentiate between these possible effects 
can be found in References [40] & [41]. 
Tables 3-5 summarize the results for competition studies 
in which small amounts of acetohexamide, tolbutamide or 
gliclazide were injected onto columns that contained nor-
mal HSA or glycated HSA and various fatty acids in the 
mobile phase. The overall trends noted in this study were 
in agreement with Reference [20] and the results in the pre-
vious section, in which most of the combinations of fatty 
acids and sulfonylurea drugs gave a decrease in binding 
for both normal HSA and glycated HSA as the concentra-
tion of fatty acids in the mobile phase was increased. This 
decrease in binding was indicated in the chromatographic 
studies by a decrease in the retention time of the injected 
drug and a decrease in its retention factor (k), or an in-
crease in the value of 1/k, as the fatty acid concentration 
was raised. 
When plots were prepared of 1/k versus fatty acid con-
centration, many of these graphs gave a linear increase in 
1/k under the conditions used in this study, as shown in 
(Figure 4). As illustrated in this figure, and by the best-fit 
parameters provided in the Supportive/Supplementary 
Material, many of the combinations of drugs and fatty ac-
ids gave similar shifts in retention for normal HSA versus 
glycated HSA. This similarity in trends suggested that the 
same general regions and types of interactions between the 
drugs and fatty acids were present in both the normal HSA 
and glycated HSA. However, the glycated HSA also tended 
to have a larger change in binding, which confirmed that 
glycation could alter these interactions [14, 20-25]. 
The linear plots of 1/k versus fatty acid concentration 
that were seen for many of the sulfonylurea drugs and 
fatty acids suggested that some type of direct competition 
was present between these solutes under these conditions, 
as predicted by Equation (1) [40, 41]. 
1  =    
KaI VM [I]   +
      VM                             (1) 
                      k           KaAmL             KaAmL  
According to Equation (1), a linear relationship would 
be expected between 1/k for an injected drug (A) and the 
concentration of a fatty acid (I) in the mobile phase for a 
system that has direct competition at a single site or a clus-
ter of sites with similar binding affinities for A and I [40, 
46, 47], as occurs for sulfonylurea drugs at Sudlow sites I 
and II [21-24]. The terms KaA  and KaI in Equation (1) are the 
association equilibrium constants (i.e., where Ka is the re-
ciprocal of the dissociation equilibrium constant, Kd) for the 
drug and fatty acid with an immobilized binding agent in 
the column (e.g., normal HSA or glycated HSA), VM  is the 
column void volume, and mL is the moles of binding sites 
in the column. 
Based on Equation (1) it was possible to classify each 
drug and fatty acid combination with regards to whether 
the system involved direct competition or a mixed-mode 
interaction (e.g., allosteric interactions plus direct competi-
tion). These classifications are provided in Tables 3-5. Al-
though similar classifications were seen for normal HSA 
and glycated HSA with the tested drugs and many of the 
fatty acids, quite different behavior was seen in some cases. 
For instance, lauric acid and linoleic acid gave mixed-mode 
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Table 3. Change in the Reciprocal of the Retention Factor (1/k) for Acetohexamide in the Presence of Increasing Concentrations 
of Fatty Acids Applied to Normal HSA and Glycated HSA Columns 
 Fatty Acid  Correlation Coefficienta  Type of Competitionb 
 Lauric acid (1.5-6 nM) 
 Normal HSA  r = 0.896 (n = 6)  Mixed mode 
 Glycated HSA  r = 0.390 (n = 6)c  Direct(?)c, KaI = 9.6 (± 11.4) × 106 M–1 
 Linoleic acid (100-250 nM) 
 Normal HSA  r = 0.941 (n = 6)  Mixed mode 
 Glycated HSA  r = 0.977 (n = 7)  Direct, KaI = 1.2 (± 0.1) × 106 M–1 
 Myristic acid (4-24 nM) 
 Normal HSA  r = 0.887 (n = 6)  Direct, KaI = 5.2 (± 1.4) × 106 M–1 
 Glycated HSA  r = 0.987 (n = 6)  Direct, KaI = 1.6 (± 0.1) × 107 M–1 
 Oleic acid (125-546 nM) 
 Normal HSA  r = 0.638 (n = 6)c  Direct(?)c, KaI = 2.6 (± 1.6) × 105 M–1 
 Glycated HSA  r = 0.500 (n = 7)c  Direct(?)c, KaI = 3.2 (± 2.4) × 104 M–1 
 Palmitic acid (100-400 nM) 
 Normal HSA  r = 0.928 (n = 6)  Direct, KaI = 3.8 (± 0.8) × 105 M–1
 Glycated HSA  r = 0.966 (n = 7)  Direct(?)c, KaI = 2.0 (± 11.5) × 108 M–1 
 Stearic acid (10-80 nM) 
 Normal HSA  r = 0.854 (n = 7)  Direct, KaI = 1.0 (± 0.3) × 106 M 
 Glycated HSA  r = 0.946 (n = 8)  Direct, KaI = 3.3 (± 0.5) × 106 M–1 
a. The correlation coefficients are those obtained for a plot made according to Equation (1). 
b. The values in parentheses represent a range of ± 1 S.D. A mixed mode interaction (e.g., direct competition plus a positive 
allosteric effect) was indicated in plots made according to Equation (1) by an initial decrease and then gradual increase in the 
retention factor for the injected drug as the concentration of fatty acids in the mobile phase was increased. A decrease in the 
retention factor for the drug when there was an increase in the concentration of the fatty acids could be produced by either a net 
negative allosteric effect or direct competition; in this study, the overall fit of the results to Equation (1) generally suggested that 
direct competition was present in most of these cases. In these latter cases, the apparent value of KaI for the fatty acid, as obtained 
by using Equation (1), is provided. 
c. The correlation coefficient obtained in this case was not significant at the 95% confidence level or, in the case of palmitic acid and 
glycated HSA, the resulting value of KaI had a level of uncertainty that made it difficult to determine if direct competition was 
present in the given system. The symbol “(?)” indicates that the variation in the data was too large or the change in the retention 
factor was too small to obtain a reliable determination of exact type of interaction that was present or of the corresponding value 
of KaI in the case of direct competition.
Table 4. Change in the Reciprocal of the Retention Factor (1/k) for Gliclazide in the Presence of Increasing Concentrations of 
Fatty Acids Applied to Normal HSA and Glycated HSA Columns 
 Fatty Acid  Correlation Coefficienta  Type of Competitionb 
 Lauric acid (1.5-6 nM) 
 Normal HSA  r = 0.902 (n = 6)  Mixed mode 
 Glycated HSA  r = 0.513 (n = 6)c  Direct(?)c, KaI = 1.8 (±  1.5) × 107 M–1 
 Linoleic acid (100-250 nM) 
 Normal HSA  r = 0.961 (n = 7)  Mixed mode 
 Glycated HSA  r = 0.972 (n = 7)  Direct, KaI = 1.6 (± 0.2) × 106 M–1 
 Myristic acid (4-24 nM) 
 Normal HSA  r = 0.885 (n = 6)  Direct, KaI = 6.4 (± 1.7) × 106 M–1 
 Glycated HSA  r = 0.965 (n = 6)  Direct, KaI = 2.4 (± 0.3) × 107 M–1 
 Oleic acid (125-546 nM) 
 Normal HSA  r = 0.894 (n = 6)  Mixed mode 
 Glycated HSA  r = 0.796 (n = 7)  Direct, KaI = 6.2 (± 2.1) × 104 M–1 
F A t t y  A c i d s ,  g l y c A t i o n ,  A n d  d r u g  i n t e r A c t i o n s  w i t H  H u m A n  s e r u m  A l B u m i n   247
Table 5. Change in the Reciprocal of the Retention Factor (1/k) for Tolbutamide in the Presence of Increasing Concentrations of 
Fatty Acids Applied to Normal HSA and Glycated HSA Columns 
 Fatty Acid  Correlation Coefficienta  Type of Competitionb 
 Lauric acid (1.5-6 nM) 
 Normal HSA  r = 0.873 (n = 6)  Mixed mode 
 Glycated HSA  r = 0.448 (n = 6)c  Direct(?)c, KaI = 1.0 (± 1.0) × 107 M–1 
 Linoleic acid (100-250 nM) 
 Normal HSA  r = 0.954 (n = 7)  Mixed mode 
 Glycated HSA  r = 0.979 (n = 7)  Direct, KaI = 1.1 (± 0.1) × 106 M–1 
 Myristic acid (4-24 nM) 
 Normal HSA  r = 0.909 (n = 6)  Direct, KaI = 4.1 (± 0.9) × 106 M–1 
 Glycated HSA  r = 0.982 (n = 6)  Direct, KaI = 1.4 (± 0.1) × 107 M–1 
 Oleic acid (125-546 nM) 
 Normal HSA  r = 0.688 (n = 6)c  Direct(?)c, KaI = 3.8 (± 2.1) × 105 M–1 
 Glycated HSA  r = 0.901 (n = 7)  Direct, KaI = 7.1 (± 1.5) × 104 M–1 
 Palmitic acid (100-400 nM) 
 Normal HSA  r = 0.926 (n = 6)  Direct, KaI = 3.1 (± 0.6) × 105 M–1 
 Glycated HSA  r = 0.936 (n = 6)  Direct(?)c, KaI = 2.6 (± 2.6) × 107 M–1 
 Stearic acid (10-80 nM) 
 Normal HSA  r = 0.890 (n = 7)  Direct, KaI = 6.5 (± 1.5) × 105 M–1
 Glycated HSA  r = 0.973 (n = 8)  Direct, KaI = 3.0 (± 0.3) × 106 M–1 
a. The correlation coefficients are those obtained for a plot made according to Equation (1). 
b. The values in parentheses represent a range of ± 1 S.D. A mixed mode interaction (e.g., direct competition plus a positive 
allosteric effect) was indicated in plots made according to Equation (1) by an initial decrease and then gradual increase in the 
retention factor for the injected drug as the concentration of fatty acids in the mobile phase was increased. A decrease in the 
retention factor for the drug when there was an increase in the concentration of the fatty acids could be produced by either a net 
negative allosteric effect or direct competition; in this study, the overall fit of the results to Equation (1) generally suggested that 
direct competition was present in most of these cases. In these latter cases, the apparent value of KaI for the fatty acid, as obtained 
by using Equation (1), is provided. 
c. The correlation coefficient obtained in this case was not significant at the 95% confidence level or, in the case of palmitic acid and 
glycated HSA, the resulting value of KaI had a level of uncertainty that made it difficult to determine if direct competition was 
present in the given system. The symbol “(?)” indicates that the variation in the data was too large or the change in the retention 
factor was too small to obtain a reliable determination of exact type of interaction that was present or of the corresponding value 
of KaI in the case of direct competition.  
 Table 4, continued. 
 Fatty Acid  Correlation Coefficienta  Type of Competitionb 
 Palmitic acid (100-400 nM) 
 Normal HSA  r = 0.965 (n = 6)  Direct, KaI = 6.3 (± 0.9) × 105 M–1 
 Glycated HSA  r = 0.905 (n = 7)  Direct(?)c, KaI = 4.5 (± 10.2) × 107 M–1 
 Stearic acid (10-80 nM) 
 Normal HSA  r = 0.885 (n = 7)  Direct, KaI = 7.4 (± 1.8) × 105 M–1 
 Glycated HSA  r = 0.982 (n = 8)  Direct, KaI = 3.6 (± 0.3) × 106 M–1 
a. The correlation coefficients are those obtained for a plot made according to Equation (1). 
b. The values in parentheses represent a range of ± 1 S.D. A mixed mode interaction (e.g., direct competition plus a positive 
allosteric effect) was indicated in plots made according to Equation (1) by an initial decrease and then gradual increase in the 
retention factor for the injected drug as the concentration of fatty acids in the mobile phase was increased. A decrease in the 
retention factor for the drug when there was an increase in the concentration of the fatty acids could be produced by either a net 
negative allosteric effect or direct competition; in this study, the overall fit of the results to Equation (1) generally suggested that 
direct competition was present in most of these cases. In these latter cases, the apparent value of KaI for the fatty acid, as obtained 
by using Equation (1), is provided. 
c. The correlation coefficient obtained in this case was not significant at the 95% confidence level or, in the case of palmitic acid and 
glycated HSA, the resulting value of KaI had a level of uncertainty that made it difficult to determine if direct competition was 
present in the given system. The symbol “(?)” indicates that the variation in the data was too large or the change in the retention 
factor was too small to obtain a reliable determination of exact type of interaction that was present or of the corresponding value 
of KaI in the case of direct competition.
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interactions on the normal HSA column for all of the drugs 
but gave confirmed or possible direct competition with 
these drugs on the glycated HSA column. These differ-
ences again indicated that glycation can affect the types of 
interactions that occur between fatty acids and sulfonyl-
urea drugs, even at low fatty acid concentrations. 
It was further possible to use Equation (1) and the best-
fit parameters of the plots for systems found to have di-
rect competition to estimate the overall value of KaI for each 
fatty acid at its site(s) of competition with an injected drug. 
These values were obtained by finding the ratio of the 
slopes to the intercepts for plots of 1/k versus [I]. The re-
sulting values of KaI are provided in Tables 3-5 and were in 
the general range of 105-108 M–1. These results gave good 
agreement with association equilibrium constants that 
have been reported for the same fatty acids with normal 
HSA in solution [33, 39]. 
A change in KaI was often seen for fatty acids when go-
ing from normal HSA to glycated HSA even in cases for 
which similar types of interactions were seen between the 
fatty acid and a sulfonylurea drug. For example, acetohex-
amide, tolbutamide and gliclazide all gave a decrease in re-
tention in the presence of myristic acid and stearic acid on 
both the normal HSA and glycated HSA columns and re-
Figure 4. Observed change in the 
retention factor (k) for gliclazide (●), 
tolbutamide (▲) and acetohexamide 
(♦) on HPLC columns containing 
immobilized (a) normal HSA or (b) 
glycated HSA and in the presence 
of mobile phases containing various 
concentrations of myristic acid. All 
values shown in this figure are the 
averages of three replicates and had 
relative standard deviations in the 
range of ±0.1–1.6%.    
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sults that were consistent with a direct competition model. 
The KaI values obtained for myristic acid at its sites of com-
petition with these drugs on normal HSA were in the range 
of 4.1-6.4 ×106 M–1 and increased to 1.4-2.4 ×107 M–1 for gly-
cated HSA. Stearic acid also showed an increase in affin-
ity (KaI) that went from 0.65-1.0 ×106 M–1 for normal HSA 
to 3.0-3.6 ×106 M–1 for glycated HSA. These values rep-
resented a net 3.1- to 3.8- fold increase in affinity for my-
ristic acid when using glycated HSA and a 3.3- to 4.9-fold 
increase in affinity for stearic acid, with all of these differ-
ences being significant at the 95% confidence level. 
Conclusion 
Binding studies conducted by ultrafiltration and in the 
presence of various fatty acids demonstrated that an in-
crease free drug concentration, or weaker binding, gener-
ally occurred for both normal HSA and glycated HSA as 
the concentration of fatty acids was increased. Such an ef-
fect could be due to direct competition or negative allo-
steric interactions between the fatty acids and drugs. The 
only exception noted was for gliclazide in the presence of 
oleic acid and normal HSA, for which an increase in over-
all binding was noted, as could be produced through a pos-
itive allosteric effect. Small or moderate changes in bind-
ing were found to be produced by lauric acid, myristic 
acid and stearic acid, while linoleic acid and palmitic acid 
gave moderate-to-large changes in binding. Oleic acid gave 
small-to-moderate increases in free drug concentrations for 
all of the tested drugs in the presence of glycated HSA and 
for tolbutamide in the presence of normal HSA; however, a 
large increase in free drug concentration for acetohexamide 
was seen in the presence of oleic acid and normal HSA. 
Chromatographic columns containing normal HSA or 
glycated HSA were next used to examine in more detail 
the effects of glycation on the interactions between com-
mon sulfonylurea drugs and fatty acids on this protein. 
Relatively low fatty acid concentrations were employed in 
this part of the study to emphasize the initial, high affin-
ity interactions that occurred as fatty acids were added to 
the system. Although similar overall changes in retention 
were seen for most combinations of drugs and fatty acids, 
some of these systems followed a direct competition model 
while others involved a mixed-mode interaction between 
the drugs and fatty acids under the conditions used in 
this study. There were some cases in which differences oc-
curred in the interaction mechanism between normal HSA 
and glycated HSA (e.g., as seen for all of the drugs with lin-
oleic acid). Even for those systems in which the same gen-
eral type of interaction was present, changes were observed 
in the affinity of the fatty acids at their sites of competition 
with the drugs. This latter effect was noted for myristic acid 
and stearic acid with all of the investigated drugs. 
These results confirmed that glycation, as a result of the 
metabolic changes that occur during diabetes, can alter the 
binding of drugs and fatty acids with HSA. In addition, it 
was found that changes in the levels of fatty acids, as can 
also take place in diabetes, can further alter these interac-
tions through various mechanisms. Together, this research 
demonstrates the importance of considering how changes 
in the concentrations and types of metabolites (e.g., in this 
case, glucose and fatty acids) can alter the function of a 
protein such as HSA and its ability to interact with drugs 
or other agents. These effects, in turn, may alter the non-
bound fraction of a drug or solute, thus affecting the appar-
ent activity and ability of this drug or solute to bind with 
other proteins or receptors and to cross cell membranes 
[11-14, 19-25]. As a result, experiments like those described 
in this report are expected to gain in importance as greater 
emphasis is placed on personalized medicine, or on the 
role that a disease state and metabolic changes may play on 
the customization of treatment for patients [14, 24, 48, 49]. 
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